Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline (China) Investment Co. Ltd.

Division of GlaxoSmithKline PLC
www.gsk-china.com

Latest From GlaxoSmithKline (China) Investment Co. Ltd.

Mooncakes Under The Sun: Can China's ‘Name And Shame’ Rule Create Level Playing Field?

China's proposal to register all medical sales reps could lead to the eventual elimination of kickbacks to physicians. Experts say it's the first step towards creating a level compliance playground for multinational and domestic drug makers.

China Compliance

China Investment Roundup: Active Deal-Making And A Record Overseas Acquisition

Chinese pharma and biotech grew increasingly active in deal-makings in the past months, with the largest outbound acquisition on record in April, a €1.3bn takeover deal made by Creat Group to German Biotest, while domestic big pharmas allotting investment to set up biologic divisions.

China Commercial

Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals

Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.

Business Strategies Commercial

Past China Practices Come to Light As GSK Settles FCPA Probe

The US SEC has accepted a $20m payment from GSK to settle charges that it violated US legislation on foreign corrupt practices, in a decision that also throws further light on the UK-based firm's past sales inducement activities in China.

China Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • GlaxoSmithKline (China) R&D Co. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Contact Info
  • GlaxoSmithKline (China) Investment Co. Ltd.
    Phone: 10 5925 2888
    56 Mid 4th East Ring Rd.
    Chaoyang District, Beijing, 100025
    China
UsernamePublicRestriction

Register